Developer docs
API playgroundTry for free, no card

Search company profiles

NovalGen

Full company profile

uuid0008j4s

Namestring
NovalGen
Legal namestring
NovalGen Ltd.
Websiteurl
novalgen.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

NovalGen is a London-based clinical-stage biotechnology company founded in 2019 by Professor Amit Nathwani, developing multi-specific biologics based on its proprietary AutoRegulation (AR) platform technology for oncology, autoimmune, haematological, and metabolic disorders. The AR platform addresses a fundamental limitation of immunotherapy—mechanism-of-action toxicities such as cytokine release syndrome (CRS) and ICANS—by engineering biologics to self-detect risk of severe toxicities at the site of action and self-deactivate, then replenish from circulating active drug as risk subsides. The company's lead asset, NVG-222, is a half-life-extended ROR1xCD3 bispecific T-cell engager equipped with AutoRegulation and became the world's first self-regulating immunotherapy to receive MHRA Clinical Trial Authorisation (September 2025) and to dose a patient in Phase 1 (March 2026), sponsored and delivered by Cancer Research UK's Centre for Drug Development at UCLH.

NovalGen's pipeline is anchored by clinical proof-of-concept data from the precursor molecule NVG-111 (same ROR1- and CD3-binding domains without AR functionality), which demonstrated a 58% objective response rate in patients with relapsed/refractory CLL and MCL with durability to 24 months and 30% MRD4 negativity in CLL participants. The broader preclinical pipeline includes NVG-666 (AR-enabled TCE targeting CD19 for autoimmune diseases with potential outpatient use), NVG-444 (UKRI-funded bispecific FVIII mimetic for haemophilia A), and NVG-555 (bispecific checkpoint inhibitor with AR for additive-toxicity prevention). R&D operations are co-located with UCL Medical School at the Royal Free Hospital, leveraging the academic infrastructure and Professor Nathwani's UCL affiliation.

The company is pre-commercial with no disclosed revenue, no disclosed funding rounds, and operates with 11–50 employees. Its business model centers on advancing candidates through clinical development toward eventual commercialization via standard pharmaceutical supply chains upon regulatory approval. Manufacturing is outsourced to CDMO partners HALIX B.V. and Mabion. Marketing is conducted through scientific publications and conference presentations (ASCO, ASH, iwCLL, ISTH), patient organization engagement, and a corporate LinkedIn presence rather than traditional commercial channels. The leadership team and board combine academic founders with experienced biotech operators from Freeline, Kymab, Tizona, GSK, and UCB Pharma.

Short descriptiontext

NovalGen is a London-based clinical-stage biotechnology company developing multi-specific biologics via its proprietary AutoRegulation (AR) platform, enabling drugs to self-regulate immune activation and reduce toxicities. Its pipeline spans oncology, autoimmune, and metabolic disorders, with the AR-enabled NVG-222 in Phase 1.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bispecific antibody therapies, immunotherapy platform, clinical-stage biotechnology, T-cell engagers, cancer therapeutics
Industry3 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Development and Commercialization
TypeOne Time License
Description

NovalGen is a clinical-stage biotechnology company developing breakthrough multi-specific biologics. As a pre-commercial company, revenue generation is not yet active. The company's pipeline includes NVG-222 (Phase 1 for hematological malignancies and solid tumors), NVG-666 (preclinical for autoimmune diseases), and other AR-enabled candidates. Commercialization of these candidates, if approved, would represent the primary revenue stream.

novalgen.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

NovalGen is a clinical-stage biotechnology company developing breakthrough multi-specific biologics based on its proprietary AutoRegulation (AR) platform technology. The company advances T-cell engagers and other bispecific antibodies for oncology, autoimmune, hematological, and metabolic disorders. Its lead candidates NVG-111 and NVG-222 are in Phase 1 clinical evaluation for ROR1-positive hematological malignancies and solid tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 58% objective clinical response rate in relapsed/refractory CLL and MCL patients treated with NVG-111
+3 more records
Product overview1 text field

NovalGen is a clinical-stage biotechnology company developing breakthrough multi-specific biologics based on its proprietary AutoRegulation (AR) platform technology. The company's pipeline comprises NVG-111 (ROR1xCD3 bispecific T-cell engager in Phase 1/2 for CLL/MCL), NVG-222 (half-life extended AR-enabled T-cell engager in Phase 1 for ROR1-positive blood cancers), NVG-666 (AR-enabled TCE for autoimmune diseases), NVG-444 (bispecific FVIII mimetic for haemophilia A), and NVG-555 (bispecific checkpoint inhibitor). The AutoRegulation platform serves as the core technology enabling multiple therapeutic candidates to self-regulate immune activation, reducing toxicity while maintaining efficacy.

Product and service6 records
1NVG-222
CategoryClinical-stage Therapeutic
Description

First therapeutic candidate equipped with NovalGen's proprietary AutoRegulation (AR) platform; a half-life-extended bispecific T-cell engager targeting ROR1 and CD3, designed to self-inactivate in response to T cell overactivation to prevent cytokine-mediated toxicities while maintaining therapeutic efficacy. Indicated for ROR1-positive hematological malignancies and solid tumors. Currently in Phase 1 clinical trial sponsored by Cancer Research UK's Centre for Drug Development with first patient dosed March 2026.

2NVG-111
CategoryClinical-stage Therapeutic
Description

First-in-class bispecific antibody T-cell engager simultaneously binding CD3 on T-cells and ROR1 on tumor cells, redirecting endogenous T-cells to tumor sites for treatment of Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). Completed Phase 1/2 study showing 58% objective response rate.

3NVG-666
CategoryPre-clinical Therapeutic
Description

AutoRegulation-enabled T-cell engager for treatment of autoimmune diseases, targeting CD19-positive cells to eliminate autoreactive B cells implicated in autoimmune disease progression. The AR platform prevents mode-of-action-related toxicities, potentially enabling outpatient treatment settings. Pre-clinical stage.

4NVG-444
CategoryPre-clinical Therapeutic
Description

UKRI-funded bispecific factor VIII mimetic antibody for haemophilia A, equipped with AutoRegulation technology to prevent thrombotic events and microangiopathies associated with conventional FVIII mimetics. Pre-clinical stage.

5NVG-555
CategoryPre-clinical Therapeutic
Description

Bispecific checkpoint inhibitor antagonising two independent checkpoint pathways, equipped with AutoRegulation technology to prevent additive toxicities associated with checkpoint inhibitor approaches. Pre-clinical stage.

6AutoRegulation (AR) Platform
CategoryTechnology Platform
Description

Proprietary platform technology that integrates self-regulating capabilities into a range of immunotherapies (T-cell engagers, bispecific antibodies, CAR-T cells, factor VIII mimetics), enabling drugs to self-inactivate in response to biological signals indicating risk of severe toxicities and to replenish from circulating active drug as risk reduces. Target-agnostic and modality-agnostic licensable platform.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Cancer Research UK's Centre for Drug Development is sponsoring and delivering the Phase 1 clinical trial of NVG-222. Cancer Research Horizons manages the commercial partnership between NovalGen and Cancer Research UK. The collaboration leverages CRUK's unparalleled commitment to pioneering therapies and expertise in advancing novel treatments into the clinic. The trial is led by Chief Investigator Dr. William Townsend at UCLH.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-23
Description

Strategic development and manufacturing partnership for NVG-222. Mabion, a European biologics CDMO, manufactured the first batch of NVG-222 for first-in-human clinical trials under license agreement. The partnership leverages Mabion's manufacturing and development capabilities to minimize pharmaceutical production risk and provides a platform for future collaboration on NovalGen's pipeline.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-02-22
Description

Strategic manufacturing partnership for clinical supply of NovalGen's therapies. HALIX, a contract development and manufacturing organization (CDMO) based in Leiden, Netherlands, successfully completed GMP manufacture of NVG-111 from drug substance to drug product and final release. The partnership enabled efficient technology transfer and successful GMP manufacturing campaign.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership for research and development. NovalGen's founder and CEO, Professor Amit Nathwani, is a UCL Professor of Haematology. The company maintains laboratory and office space at UCL Medical School, Royal Free Hospital. UCL investigators serve as principal investigators on clinical trials.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based clinical-stage biotech developing programmed T-cell therapies for cancer, with similar London footprint and academic founder origins. Comparable in geography, stage, and focus on safer T-cell-directed therapies for hematological malignancies.

TypeDirect peer
Description

Clinical-stage biotech with proprietary DART and TRIDENT platforms for bispecific antibodies, including T-cell engagers in oncology. Comparable as a multi-specific antibody platform company with similar target classes and clinical focus.

TypeBroad incumbent
Description

Large established biotech with proprietary DuoBody bispecific antibody platform, partnered with AbbVie (epcoritamab) and others. Represents the broad incumbent player in bispecific antibodies and validates the commercial potential of the modality NovalGen is pursuing.

TypeDirect peer
Description

Developed COBRA platform of conditionally active T-cell engagers designed to be activated only in the tumor microenvironment, acquired by Takeda. The COBRA concept of conditional/safe T-cell engagement is the most mechanistically similar peer to NovalGen's AR platform.

TypeDirect peer
Description

Developed T-cell engagers using a proprietary tri-specific T-cell activating construct (TriTAC) platform, now part of Merck following acquisition. Direct competitor in the safer T-cell engager space with comparable targeting strategies.

TypeDirect peer
Description

UK-based clinical-stage biotech developing T-cell engagers (Humabody platform) for oncology, including CD3-binding bispecifics against tumor targets. Highly comparable in geography, stage, modality, and clinical focus on safer T-cell engagers.

TypeDirect peer
Description

Swedish clinical-stage biotech developing bispecific antibodies (e.g., mitazalimab, ATOR-4066) with proprietary technology to enhance tumor-directed immune activation. Comparable as a smaller European bispecific antibody developer.

TypeDirect peer
Description

Clinical-stage biotech with Azymetric and Effi-function platforms for bispecific and multifunctional antibodies, including T-cell engagers in oncology. Comparable as a bispecific antibody platform company with multiple pipeline programs.

TypeDirect peer
Description

Swiss clinical-stage biotech developing DARPin-based multi-specific therapeutics, including immune-cell engaging candidates in oncology. Comparable as a non-antibody scaffold multi-specific platform company with similar modality innovation.

TypeDirect peer
Description

Bispecific antibody platform company developing Fcab-based multi-specifics, with clinical-stage TCE programs in oncology. Directly comparable as a bispecific antibody developer with platform technology at similar stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NovalGen

Cancer Immunotherapynovalgen.com

NovalGen is a London-based clinical-stage biotechnology company developing multi-specific biologics via its proprietary AutoRegulation (AR) platform, enabling drugs to self-regulate immune activation and reduce toxicities. Its pipeline spans oncology, autoimmune, and metabolic disorders, with the AR-enabled NVG-222 in Phase 1.

What NovalGen does

NovalGen is a London-based clinical-stage biotechnology company founded in 2019 by Professor Amit Nathwani, developing multi-specific biologics based on its proprietary AutoRegulation (AR) platform technology for oncology, autoimmune, haematological, and metabolic disorders. The AR platform addresses a fundamental limitation of immunotherapy—mechanism-of-action toxicities such as cytokine release syndrome (CRS) and ICANS—by engineering biologics to self-detect risk of severe toxicities at the site of action and self-deactivate, then replenish from circulating active drug as risk subsides. The company's lead asset, NVG-222, is a half-life-extended ROR1xCD3 bispecific T-cell engager equipped with AutoRegulation and became the world's first self-regulating immunotherapy to receive MHRA Clinical Trial Authorisation (September 2025) and to dose a patient in Phase 1 (March 2026), sponsored and delivered by Cancer Research UK's Centre for Drug Development at UCLH.

NovalGen's pipeline is anchored by clinical proof-of-concept data from the precursor molecule NVG-111 (same ROR1- and CD3-binding domains without AR functionality), which demonstrated a 58% objective response rate in patients with relapsed/refractory CLL and MCL with durability to 24 months and 30% MRD4 negativity in CLL participants. The broader preclinical pipeline includes NVG-666 (AR-enabled TCE targeting CD19 for autoimmune diseases with potential outpatient use), NVG-444 (UKRI-funded bispecific FVIII mimetic for haemophilia A), and NVG-555 (bispecific checkpoint inhibitor with AR for additive-toxicity prevention). R&D operations are co-located with UCL Medical School at the Royal Free Hospital, leveraging the academic infrastructure and Professor Nathwani's UCL affiliation.

The company is pre-commercial with no disclosed revenue, no disclosed funding rounds, and operates with 11–50 employees. Its business model centers on advancing candidates through clinical development toward eventual commercialization via standard pharmaceutical supply chains upon regulatory approval. Manufacturing is outsourced to CDMO partners HALIX B.V. and Mabion. Marketing is conducted through scientific publications and conference presentations (ASCO, ASH, iwCLL, ISTH), patient organization engagement, and a corporate LinkedIn presence rather than traditional commercial channels. The leadership team and board combine academic founders with experienced biotech operators from Freeline, Kymab, Tizona, GSK, and UCB Pharma.

NovalGen firmographics

Firmographics
Name
NovalGen
Legal name
NovalGen Ltd.
Website
https://novalgen.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
NovalGen is a London-based clinical-stage biotechnology company developing multi-specific biologics via its proprietary AutoRegulation (AR) platform, enabling drugs to self-regulate immune activation and reduce toxicities. Its pipeline spans oncology, autoimmune, and metabolic disorders, with the AR-enabled NVG-222 in Phase 1.
Ownership category
akta.pro rank

NovalGen industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Bispecific antibody therapies
  • Immunotherapy platform
  • Clinical-stage biotechnology
  • T-cell engagers
  • Cancer therapeutics

Where NovalGen is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

NovalGen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

  1. Biopharmaceutical Development and Commercialization: NovalGen is a clinical-stage biotechnology company developing breakthrough multi-specific biologics. As a pre-commercial company, revenue generation is not yet active. The company's pipeline includes NVG-222 (Phase 1 for hematological malignancies and solid tumors), NVG-666 (preclinical for autoimmune diseases), and other AR-enabled candidates. Commercialization of these candidates, if approved, would represent the primary revenue stream.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

NovalGen product offering

Product offering

Core offering

NovalGen is a clinical-stage biotechnology company developing breakthrough multi-specific biologics based on its proprietary AutoRegulation (AR) platform technology. The company advances T-cell engagers and other bispecific antibodies for oncology, autoimmune, hematological, and metabolic disorders. Its lead candidates NVG-111 and NVG-222 are in Phase 1 clinical evaluation for ROR1-positive hematological malignancies and solid tumors.

Product overview

NovalGen is a clinical-stage biotechnology company developing breakthrough multi-specific biologics based on its proprietary AutoRegulation (AR) platform technology. The company's pipeline comprises NVG-111 (ROR1xCD3 bispecific T-cell engager in Phase 1/2 for CLL/MCL), NVG-222 (half-life extended AR-enabled T-cell engager in Phase 1 for ROR1-positive blood cancers), NVG-666 (AR-enabled TCE for autoimmune diseases), NVG-444 (bispecific FVIII mimetic for haemophilia A), and NVG-555 (bispecific checkpoint inhibitor). The AutoRegulation platform serves as the core technology enabling multiple therapeutic candidates to self-regulate immune activation, reducing toxicity while maintaining efficacy.

Differentiator

Problem solved

Functional benefit

Products and services

  • NVG-222 First therapeutic candidate equipped with NovalGen's proprietary AutoRegulation (AR) platform; a half-life-extended bispecific T-cell engager targeting ROR1 and CD3, designed to self-inactivate in response to T cell overactivation to prevent cytokine-mediated toxicities while maintaining therapeutic efficacy. Indicated for ROR1-positive hematological malignancies and solid tumors. Currently in Phase 1 clinical trial sponsored by Cancer Research UK's Centre for Drug Development with first patient dosed March 2026.
  • NVG-111 First-in-class bispecific antibody T-cell engager simultaneously binding CD3 on T-cells and ROR1 on tumor cells, redirecting endogenous T-cells to tumor sites for treatment of Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). Completed Phase 1/2 study showing 58% objective response rate.
  • NVG-666 AutoRegulation-enabled T-cell engager for treatment of autoimmune diseases, targeting CD19-positive cells to eliminate autoreactive B cells implicated in autoimmune disease progression. The AR platform prevents mode-of-action-related toxicities, potentially enabling outpatient treatment settings. Pre-clinical stage.
  • NVG-444 UKRI-funded bispecific factor VIII mimetic antibody for haemophilia A, equipped with AutoRegulation technology to prevent thrombotic events and microangiopathies associated with conventional FVIII mimetics. Pre-clinical stage.
  • NVG-555 Bispecific checkpoint inhibitor antagonising two independent checkpoint pathways, equipped with AutoRegulation technology to prevent additive toxicities associated with checkpoint inhibitor approaches. Pre-clinical stage.
  • AutoRegulation (AR) Platform Proprietary platform technology that integrates self-regulating capabilities into a range of immunotherapies (T-cell engagers, bispecific antibodies, CAR-T cells, factor VIII mimetics), enabling drugs to self-inactivate in response to biological signals indicating risk of severe toxicities and to replenish from circulating active drug as risk reduces. Target-agnostic and modality-agnostic licensable platform.

Quantifiable outcome

  • 58% objective clinical response rate in relapsed/refractory CLL and MCL patients treated with NVG-111
  • +3 more outcomes

Companies that use NovalGen

Customer profile

Segments3 records

Ideal customer profiles3 records

NovalGen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

NovalGen partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Cancer Research UK (CRUK) - Centre for Drug DevelopmentcoreStrategic or Co-development Partner · 17 March 2026Cancer Research UK's Centre for Drug Development is sponsoring and delivering the Phase 1 clinical trial of NVG-222. Cancer Research Horizons manages the commercial partnership between NovalGen and Cancer Research UK. The collaboration leverages CRUK's unparalleled commitment to pioneering therapies and expertise in advancing novel treatments into the clinic. The trial is led by Chief Investigator Dr. William Townsend at UCLH.
  • MabioncoreTechnology or Integration · 23 June 2025Strategic development and manufacturing partnership for NVG-222. Mabion, a European biologics CDMO, manufactured the first batch of NVG-222 for first-in-human clinical trials under license agreement. The partnership leverages Mabion's manufacturing and development capabilities to minimize pharmaceutical production risk and provides a platform for future collaboration on NovalGen's pipeline.
  • HALIX B.V.coreTechnology or Integration · 22 February 2021Strategic manufacturing partnership for clinical supply of NovalGen's therapies. HALIX, a contract development and manufacturing organization (CDMO) based in Leiden, Netherlands, successfully completed GMP manufacture of NVG-111 from drug substance to drug product and final release. The partnership enabled efficient technology transfer and successful GMP manufacturing campaign.
  • University College London (UCL)coreStrategic or Co-development PartnerAcademic partnership for research and development. NovalGen's founder and CEO, Professor Amit Nathwani, is a UCL Professor of Haematology. The company maintains laboratory and office space at UCL Medical School, Royal Free Hospital. UCL investigators serve as principal investigators on clinical trials.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

NovalGen competitors and assessment

Company assessment

Direct peers

  • Autolus Therapeutics: UK-based clinical-stage biotech developing programmed T-cell therapies for cancer, with similar London footprint and academic founder origins. Comparable in geography, stage, and focus on safer T-cell-directed therapies for hematological malignancies.
  • Macrogenics: Clinical-stage biotech with proprietary DART and TRIDENT platforms for bispecific antibodies, including T-cell engagers in oncology. Comparable as a multi-specific antibody platform company with similar target classes and clinical focus.
  • Maverick Therapeutics: Developed COBRA platform of conditionally active T-cell engagers designed to be activated only in the tumor microenvironment, acquired by Takeda. The COBRA concept of conditional/safe T-cell engagement is the most mechanistically similar peer to NovalGen's AR platform.
  • Harpoon Therapeutics: Developed T-cell engagers using a proprietary tri-specific T-cell activating construct (TriTAC) platform, now part of Merck following acquisition. Direct competitor in the safer T-cell engager space with comparable targeting strategies.
  • Crescendo Biologics: UK-based clinical-stage biotech developing T-cell engagers (Humabody platform) for oncology, including CD3-binding bispecifics against tumor targets. Highly comparable in geography, stage, modality, and clinical focus on safer T-cell engagers.
  • Alligator Bioscience: Swedish clinical-stage biotech developing bispecific antibodies (e.g., mitazalimab, ATOR-4066) with proprietary technology to enhance tumor-directed immune activation. Comparable as a smaller European bispecific antibody developer.
  • Zymeworks: Clinical-stage biotech with Azymetric and Effi-function platforms for bispecific and multifunctional antibodies, including T-cell engagers in oncology. Comparable as a bispecific antibody platform company with multiple pipeline programs.
  • Molecular Partners: Swiss clinical-stage biotech developing DARPin-based multi-specific therapeutics, including immune-cell engaging candidates in oncology. Comparable as a non-antibody scaffold multi-specific platform company with similar modality innovation.
  • F-star Therapeutics: Bispecific antibody platform company developing Fcab-based multi-specifics, with clinical-stage TCE programs in oncology. Directly comparable as a bispecific antibody developer with platform technology at similar stage.

Broad incumbents

  • Genmab: Large established biotech with proprietary DuoBody bispecific antibody platform, partnered with AbbVie (epcoritamab) and others. Represents the broad incumbent player in bispecific antibodies and validates the commercial potential of the modality NovalGen is pursuing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

NovalGen social profiles

Digital presence

NovalGen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NovalGen leadership team

Management profile

Number of profiles

Profiles10 records

NovalGen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NovalGen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NovalGen

What does NovalGen do?

NovalGen is a clinical-stage biotechnology company developing breakthrough multi-specific biologics based on its proprietary AutoRegulation (AR) platform technology. The company advances T-cell engagers and other bispecific antibodies for oncology, autoimmune, hematological, and metabolic disorders. Its lead candidates NVG-111 and NVG-222 are in Phase 1 clinical evaluation for ROR1-positive hematological malignancies and solid tumors.

Is NovalGen a public or private company?

NovalGen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NovalGen founded?

NovalGen was founded in 2019. It employs 11 to 50 people.

Where is NovalGen based?

NovalGen is headquartered in London, United Kingdom, in the Europe region.

How does NovalGen make money?

One revenue line is on record: biopharmaceutical Development and Commercialization.

Who are NovalGen's main competitors?

Direct peers on record are Autolus Therapeutics, Macrogenics, Maverick Therapeutics, Harpoon Therapeutics, Crescendo Biologics, Alligator Bioscience, Zymeworks, Molecular Partners and F-star Therapeutics. Genmab is listed as a broad incumbent.

Does NovalGen have an API?

No public API is recorded for NovalGen.

What industry is NovalGen in?

NovalGen's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireNovalGen Appoints Dr Laurent Fischer as Chair of the BoardNovalGen announced the appointment of Dr. Laurent Fischer as Non-Executive Chair of the Board of Directors, effective immediately. Dr. Fischer brings over 25 years of CEO and board leadership experience across public and private biotechnology companies, having led five biopharma firms spanning oncology, ophthalmology, rare disease, and virology. The appointment coincides with NovalGen advancing its AutoRegulation immunotherapy platform and lead asset NVG-222 into later-stage development.BioSpaceNovalGen Appoints Dr Laurent Fischer as Chair of the BoardNovalGen appointed Dr Laurent Fischer as non-executive chair of its board, effective immediately. He brings over 25 years of biopharma leadership and will guide the company's AutoRegulation platform and lead asset NVG-222 into later-stage development.GlobeNewswireNovalGen to Begin World’s First Clinical Trial for a Self-Regulating ImmunotherapyThe UK's MHRA approved the first clinical trial for NovalGen's AutoRegulating T cell engager NVG-222, targeting ROR1-positive haematological malignancies. The Phase I/II study, sponsored by Cancer Research UK, will enroll UK patients with first patient dosing expected in Q4 2025. The drug is manufactured under license by Mabion.GlobeNewswireNovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of DirectorsNovalGen appointed Dr Michael Owen and Mr Scott Clark as non-executive directors, effective January 2023. Owen brings over 40 years of experience, including co-founding Kymab, while Clark is CEO of Ambagon Therapeutics. The company is advancing its lead product NVG-111 and preclinical programs.PrwebNovalgen licenses mAbsolve's QumAb™ technology to improve the safety of therapeutic antibodiesmAbsolve licensed its QumAb antibody-silencing technology to Novalgen for evaluation in therapeutic antibodies for cancer, leukaemias, and cardiovascular disease. The technology aims to eliminate unwanted inflammatory responses, with about 50% of developing antibodies already using similar alterations. Novalgen expects the partnership to help develop safer antibody therapies.